KALA BIO, Inc. (KALA) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
KALA BIO, Inc. (KALA) trades at $0.8401 with AI Score 26/100 (Grade F). Kala Bio, Inc. Market cap: $16.3M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: May 10, 2026Analyst Coverage for KALA: KALA does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates KALA against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
KALA: 1/3 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Why this analysis is different
- A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
KALA BIO, Inc. (KALA) Healthcare & Pipeline Overview
Kala Bio, Inc. is a biopharmaceutical company specializing in nanoparticle-based therapies for eye diseases, utilizing its proprietary mucus penetrating particle (MPP) technology to improve drug delivery and efficacy. The company targets both front- and back-of-the-eye conditions, positioning itself in the ophthalmology therapeutics market.
What Is the Investment Thesis for KALA?
Kala Bio, Inc. presents a focused investment opportunity within the ophthalmology therapeutics market. The company's proprietary MPP technology offers a potential advantage in drug delivery, addressing a key limitation of existing eye disease treatments. Key value drivers include the successful development and commercialization of its pipeline candidates, particularly those targeting significant unmet needs in both front and back of the eye diseases. Growth catalysts include positive clinical trial results, regulatory approvals, and strategic partnerships. However, the company faces risks associated with clinical trial outcomes, regulatory hurdles, and competition from established pharmaceutical companies in the ophthalmology space. The company's small market capitalization and limited financial resources also pose challenges to its long-term growth prospects.
Based on FMP financials and quantitative analysis
KALA Key Highlights
Kala Bio, Inc. is a biopharmaceutical company focused on eye diseases.
- The company utilizes proprietary nanoparticle-based mucus penetrating particles (MPP) technology.
- Kala Bio's focus is on developing therapies for both front and back of the eye diseases.
- The company was founded in 2009 and is headquartered in Arlington, MA.
- Kala Bio has 38 employees.
Who Are KALA's Competitors?
KALA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ALXN Alexion Pharmaceuticals, Inc. | $182.50 | +0.00% | 60 | |
| LLY Eli Lilly and Company | $1245.69 | -2.71% | $1.17T | 97 |
| NVS Novartis AG | $160.31 | +3.73% | $305B | 57 |
| PFE Pfizer Inc. | $28.24 | +3.63% | $161B | 67 |
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are KALA's Key Strengths?
Proprietary MPP technology for enhanced drug delivery.
- Focus on unmet needs in ophthalmology.
- Experienced management team.
- Strong intellectual property portfolio.
What Are KALA's Weaknesses?
Limited financial resources.
- Dependence on successful clinical trial outcomes.
- Small market capitalization.
- Limited commercialization experience.
What Could Drive KALA Stock Higher?
Clinical trial results for lead drug candidates.
- Regulatory submissions for potential product approvals.
- Progress in research and development of new therapies.
- Potential for strategic partnerships and collaborations.
What Are the Key Risks for KALA?
Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures.
- Regulatory delays or rejections.
- Competition from established pharmaceutical companies.
- Limited financial resources.
- Dependence on key personnel.
What Are the Growth Opportunities for KALA?
- Expansion of Pipeline: Kala Bio has the opportunity to expand its pipeline by developing new therapies for additional eye diseases. By leveraging its MPP technology, the company can target a broader range of ophthalmic conditions, including rare and underserved indications. This expansion could involve both internal research and development efforts as well as strategic collaborations with other companies or research institutions. A successful pipeline expansion would diversify Kala Bio's product portfolio and increase its long-term growth potential. The timeline for this growth opportunity is ongoing, with continuous research and development efforts focused on identifying and developing new therapeutic candidates.
- Strategic Partnerships: Kala Bio can pursue strategic partnerships with larger pharmaceutical companies to accelerate the development and commercialization of its therapies. These partnerships could involve licensing agreements, co-development arrangements, or joint ventures. By collaborating with established players in the ophthalmology market, Kala Bio can gain access to additional resources, expertise, and distribution channels. Strategic partnerships can also provide validation of Kala Bio's technology and increase its visibility within the industry. The timeline for securing strategic partnerships is ongoing, with active engagement in business development activities and industry networking.
- Advancement of Clinical Programs: Kala Bio's growth is heavily dependent on the successful advancement of its clinical programs. Positive clinical trial results are essential for demonstrating the safety and efficacy of its therapies and securing regulatory approvals. The company must effectively manage its clinical trials, ensuring timely enrollment, data collection, and analysis. Successful clinical development will not only validate Kala Bio's technology but also create significant value for its shareholders. The timeline for this growth opportunity is dependent on the specific clinical trial timelines for each of its pipeline candidates.
- Regulatory Approvals: Securing regulatory approvals from agencies such as the FDA is a critical growth driver for Kala Bio. These approvals are necessary for commercializing its therapies and generating revenue. The company must navigate the complex regulatory landscape, ensuring compliance with all applicable requirements. Successful regulatory approvals will not only validate Kala Bio's technology but also provide a competitive advantage in the market. The timeline for this growth opportunity is dependent on the specific regulatory review timelines for each of its pipeline candidates.
- Commercialization of Products: The ultimate growth opportunity for Kala Bio lies in the successful commercialization of its products. This involves establishing a sales and marketing infrastructure, securing reimbursement coverage, and effectively promoting its therapies to healthcare providers and patients. Successful commercialization will drive revenue growth and establish Kala Bio as a leading player in the ophthalmology market. The timeline for this growth opportunity is dependent on securing regulatory approvals and establishing a commercial infrastructure.
What Are KALA's Competitive Advantages?
- Proprietary MPP Technology: Kala Bio's patented mucus penetrating particle (MPP) technology provides a unique advantage in drug delivery to the eye.
- Focus on Unmet Needs: The company targets specific eye diseases with limited treatment options, creating a niche market.
- Intellectual Property: Kala Bio has a portfolio of patents protecting its technology and formulations.
- Clinical Data: Positive clinical trial results can create a competitive advantage and increase the value of its therapies.
What Does KALA Do?
Kala Bio, Inc., founded in 2009 by Justin Hanes, Robert S. Langer, and Colin R. Gardner, is a biopharmaceutical company headquartered in Arlington, Massachusetts. The company is dedicated to the development and commercialization of innovative therapies for eye diseases. Kala Bio's core technology revolves around its proprietary nanoparticle-based mucus penetrating particles (MPP), designed to enhance drug delivery through the ocular mucus barrier, thereby improving therapeutic efficacy. The company's strategic focus is on addressing unmet needs in both front and back of the eye diseases. Kala Bio's innovative approach aims to overcome the challenges associated with traditional eye drop formulations, which often suffer from poor drug penetration and bioavailability. By utilizing MPP technology, Kala Bio seeks to deliver drugs more effectively to the target tissues within the eye, potentially leading to improved patient outcomes. The company's research and development efforts are geared towards creating novel therapies that can address a wide range of ophthalmic conditions, solidifying its position in the competitive biotechnology landscape.
What Products and Services Does KALA Offer?
- Develops nanoparticle-based therapies for eye diseases.
- Utilizes proprietary mucus penetrating particle (MPP) technology.
- Focuses on improving drug delivery to the eye.
- Targets both front- and back-of-the-eye conditions.
- Conducts research and development of novel ophthalmic treatments.
- Seeks to commercialize innovative therapies for unmet needs in ophthalmology.
How Does KALA Make Money?
- Develops and patents novel drug formulations using MPP technology.
- Conducts preclinical and clinical trials to demonstrate safety and efficacy.
- Seeks regulatory approvals from agencies like the FDA.
- May partner with larger pharmaceutical companies for commercialization.
- Generates revenue through product sales and licensing agreements.
What Industry Does KALA Operate In?
Kala Bio operates within the biotechnology industry, specifically targeting the ophthalmology therapeutics market. This market is characterized by increasing prevalence of eye diseases such as glaucoma, macular degeneration, and dry eye syndrome, driving demand for innovative treatments. The competitive landscape includes established pharmaceutical companies and emerging biotech firms developing novel therapies. Kala Bio's MPP technology positions it as a potential disruptor by addressing the limitations of traditional drug delivery methods in the eye. The ophthalmology market is projected to continue growing, driven by an aging population and advancements in diagnostic and therapeutic technologies.
Who Are KALA's Key Customers?
- Patients with eye diseases such as glaucoma, macular degeneration, and dry eye syndrome.
- Ophthalmologists and other eye care professionals.
- Hospitals and clinics.
- Pharmacies and other distributors of pharmaceutical products.
Forward Outlook
Wall Street analysts project KALA BIO, Inc. revenue of about $25.0M for fiscal 2026, with EPS near $-26.50.
KALA Valuation & Market Position
With a $16.3M market cap, KALA BIO, Inc. sits in the micro-cap segment of the market. Relative to its peer group, KALA's quantitative score of 26/100 is below the peer average of 71/100.
Key Financial Metrics
Its free cash flow yield is -69.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 7.91 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -140.2%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
KALA BIO, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Company Profile
KALA BIO, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Arlington, US. The company is led by CEO Avi Minkowitz. KALA has traded publicly since 2017.
KALA Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Proprietary MPP technology for enhanced drug delivery.
- Focus on unmet needs in ophthalmology.
- Experienced management team.
- Strong intellectual property portfolio.
Bear Case
- Limited financial resources.
- Dependence on successful clinical trial outcomes.
- Small market capitalization.
- Limited commercialization experience.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
KALA Latest News
No recent news available for KALA.
KALA Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for KALA.
Price Targets
Wall Street price target analysis for KALA.
KALA MoonshotScore
What does this score mean?
The MoonshotScore rates KALA 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Latest KALA BIO, Inc. Analysis
Leadership: Avi Minkowitz
Unknown
Information about Avi Minkowitz's background is not available in the provided data. Therefore, a detailed biography cannot be provided. Further research would be required to gather information about his career history, education, and previous roles.
Track Record: Due to the lack of available information, it is not possible to provide a summary of Avi Minkowitz's track record, including key achievements, strategic decisions, and company milestones under his leadership. Additional research would be necessary to assess his performance and contributions to Kala Bio, Inc.
KALA BIO, Inc. Healthcare Stock: Key Questions Answered
What does the AI Score mean for KALA?
KALA holds an AI Score of 26/100 (Grade: F). This is an educational research signal, not a buy or sell recommendation. Kala Bio, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for eye diseases using its proprietary nanoparticle-based mucus penetrating particles …
What does KALA BIO, Inc. do?
KALA BIO, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for eye diseases. The company's core technology is its proprietary mucus penetrating particle (MPP) technology, which enables enhanced drug delivery to the eye. KALA BIO targets both front- and back-of-the-eye conditions, aiming to address unmet needs in the treatment of various ophthalmic disorders.
What do analysts say about KALA stock?
Analyst coverage of KALA BIO, Inc. is currently unavailable based on the provided data. Therefore, a summary of analyst consensus, key valuation metrics, and growth considerations cannot be provided. Further research would be required to gather analyst reports and assess their perspectives on the company's prospects.
What are the main risks for KALA?
KALA BIO, Inc. faces several risks inherent to the biotechnology industry. One major risk is the potential for clinical trial failures, which could significantly impact the company's pipeline and valuation. Regulatory hurdles also pose a risk, as delays or rejections of product approvals could delay commercialization.
How does KALA BIO, Inc. navigate regulatory approval processes?
KALA BIO, Inc. navigates regulatory approval processes by adhering to strict guidelines set by agencies like the FDA. This involves conducting comprehensive preclinical and clinical trials to demonstrate the safety and efficacy of its therapies. The company prepares detailed regulatory submissions, including data on manufacturing processes, quality control, and clinical outcomes.
What is KALA BIO, Inc.'s drug pipeline status?
The provided data does not contain specific details regarding KALA BIO, Inc.'s drug pipeline status. Therefore, a summary of the company's clinical pipeline stages, key therapeutic areas, and upcoming catalysts cannot be provided. Further research would be required to gather information on the company's current pipeline candidates, their respective stages of development, and any anticipated milestones.
What are the key factors to evaluate for KALA?
KALA BIO, Inc. (KALA) holds an AI score of 26/100 (low). presents a focused investment opportunity within the ophthalmology therapeutics market. Not financial advice.
How frequently does KALA data refresh on this page?
KALA's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven KALA's recent stock price performance?
KALA BIO, Inc. (KALA) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary MPP technology for enhanced drug delivery. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited financial data available.
- Analyst consensus data not available.
- CEO background information incomplete.